PepGen To Present Research on Enhanced Delivery Treatments for Neuromuscular Disease at Two Scientific Conferences in September
BOSTON, Sept. 20, 2021 (GLOBE NEWSWIRE) -- PepGen, Inc. ,a company advancing next-generation oligonucleotide therapies for neuromuscular diseases,today announced that Chief Executive Officer James McArthur, Ph.D., will present on Pepgens Enhanced Delivery Oligonucleotide (EDO) therapeutic platform at two scientific conferences in September.
- BOSTON, Sept. 20, 2021 (GLOBE NEWSWIRE) -- PepGen, Inc. ,a company advancing next-generation oligonucleotide therapies for neuromuscular diseases,today announced that Chief Executive Officer James McArthur, Ph.D., will present on Pepgens Enhanced Delivery Oligonucleotide (EDO) therapeutic platform at two scientific conferences in September.
- Dr. McArthur will discuss preclinical data supporting development of PepGens lead candidates in Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1) at TIDES USA: Oligonucleotide & Peptide Therapeutics, taking place in Boston and virtually from September 20-30, 2021, and the Oligonucleotide Therapeutics Society (OTS) 2021 Virtual Conference, taking place from September 26-29, 2021.
- Dr. McArthurs presentation at the OTS conference will include a presentation of data for PepGens lead DMD program, EDO51, demonstrating robust exon-skipping across skeletal and cardiac tissues in non-human primates.
- Presentation details are as follows: